Lisheng Pharmaceutical: Net profit expected to increase by 125.6% to 416 million yuan by 2025, with 11 new projects approved during the reporting period

On March 24, Lisheng Pharmaceutical announced its 2025 annual report. The company’s operating revenue was 1.39 billion yuan, up 4.2% year-over-year; net profit attributable to shareholders was 416 million yuan, up 125.6%; non-recurring net profit attributable to shareholders was 169 million yuan, up 63.6%; net operating cash flow was 247 million yuan, up 180.4%; and EPS (fully diluted) was 1.6159 yuan.

In the fourth quarter, the company’s operating revenue was 385 million yuan, up 23.2% year-over-year; net profit attributable to shareholders was 45.54 million yuan, up 198.1%; non-recurring net profit turned profitable from a loss of 3.31 million yuan in the same period last year, reaching 41.80 million yuan; EPS was 0.1768 yuan.

As of the end of the fourth quarter, the company’s total assets were 5.584 billion yuan, a decrease of 3.5% from the end of the previous year; net assets attributable to shareholders were 4.628 billion yuan, down 3.0%.

The announcement mentioned that during the reporting period, the company focused on core technology and product R&D, emphasizing key areas such as synthetic biology and improved new drugs. It completed the establishment of 11 new projects, including 2 innovative improved drugs that fill gaps in the market; it completed 36 patent applications and 14 patent grants, and advanced 19 product filings with 10 approvals, continuously enriching the R&D pipeline and enhancing product core competitiveness.

Additionally, the company deepened collaborative innovation and成果转化, signing a strategic cooperation agreement with Tianjin University of Technology to jointly tackle a drug co-crystal project, integrating university research resources to address internal R&D gaps; it established a linkage mechanism among R&D, production, and sales, incorporating market and production feedback from the project initiation stage to ensure R&D results meet market needs, significantly improving conversion efficiency and rapidly translating R&D成果 into operational benefits.

(Lisheng Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare